Dag Larsson is the Senior Policy Expert at Lif - the research-based pharmaceutical companies. Photo: Gunilla Lundström

Av Saga Buskhe den 28 november 2023 10:51

When the UN’s intellectual property organisation WIPO’s annual Global Innovation Index was presented at the end of September, Sweden came in second, surpassed only by Switzerland. This is the 13th consecutive year that Sweden has been ranked in the world’s top three, but how does the Swedish pharmaceutical industry compare with other countries?

The Swedish innovation model has changed in recent years, says Dag Larsson, Senior Policy Expert at Lif - the research-based pharmaceutical companies.

“We are relatively good, but we can do better. We are working with an excellent toolbox. We have had a new life science strategy for a few years now, and work is underway on the research and innovation bill, for which I know that many proposals have been made,” says Dag Larsson to Life Science Sweden.

“To be able to turn research into a product, you need knowledge about the process and investors willing to take risks. In Sweden, we have had a tradition of being particularly involved in the clinical development of medicines.”

Today, several small companies in Sweden are collaborating with larger companies to drive the development of medicines, and there is considerable activity in this area. However, as a country, we are not very good at taking innovations directly to the patients, says Dag Larsson.

“There is a paradox. As a country, we often rank high on innovation indexes, but we don’t really manage to turn innovation into something big that can contribute to society as a whole.”

At the conference Pharma Outsourcing on 5 December, Dag Larsson will talk about the industry’s innovation model and how Sweden compares with other countries.

Se mer om eventet Artikeln är en del av vårt tema om News in English.